A role for IL-6 in hepatic cancer was proposed earlier by Naugler et al. [103], who observed that male rats developed more HCC than female rats after DEN administration, proposed that this gender difference (which was also observed in human studies showing that males have a higher HCC incidence than females [102], could be attributed to lower IL-6 production in females. Here, IL6 is linked to liver cancer.